Bragar Eagel & Squire, P.C. announced class action lawsuits against PayPal and REGENXBIO. PayPal's lawsuit claims the company misled investors about its revenue outlook and growth prospects, leading to a stock drop after disappointing financial results and CEO transition. REGENXBIO's lawsuit alleges the company concealed adverse facts about its gene therapy trial, causing a significant stock price decline after the FDA placed a clinical hold. Investors have deadlines in April 2026 to join as lead plaintiffs.
Stripe and Advent International have jointly proposed to acquire PayPal in a deal valued at over $53 billion, offering $60.50 per share, a 28% premium over the previous close. The proposal, backed by $50 billion in financing, aims to combine PayPal's...
PayPal (PYPL) is rated a Strong Buy due to its undervalued stock price and strong financials, including $6.98 billion in cash and solid Q1 growth with 11% TPV and 25% adjusted free cash flow increases. The recent $53 billion buyout offer from Stripe ...
Payments company Stripe and private equity firm Advent International jointly offered to acquire PayPal for $60.50 per share, valuing the company at over $53 billion, a 28% premium to its recent closing price. The offer, backed by about $50 billion in...
PayPal's stock surged 16% in pre-market trading following reports that Stripe and Advent International made a $53 billion joint takeover offer. The bid values PayPal at $60.50 per share, a 28% premium over its recent closing price, and is backed by $...
